Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4XL6Z
|
|||
| Drug Name |
Vixarelimab
|
|||
| Synonyms |
RG6536
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Idiopathic pulmonary fibrosis [ICD-11: CB03.4; ICD-10: J84.1; ICD-9: 516.3] | Phase 1 | [1] | |
| Pruritus [ICD-11: EC90; ICD-10: L29, L29.9; ICD-9: 698] | Phase 1 | [2] | ||
| Company |
Roche
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oncostatin-M-specific receptor beta (OSMR) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05785624) A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared With Placebo in Patients With Idiopathic Pulmonary Fibrosis and in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT03816891) A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects With Prurigo Nodularis. U.S.National Institutes of Health. | |||
| REF 3 | Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor beta antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. EClinicalMedicine. 2023 Feb 3;57:101826. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.